logo
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Business Wire22-05-2025

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.
The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research.
Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.
This agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand QIAGEN's portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This unique platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways.
"Through our collaboration with ID Solutions, we are reinforcing our commitment at QIAGEN to providing comprehensive dPCR solutions on QIAcuity that address critical needs in oncology research," said Simona Grandits, Vice President, Head of Commercial Operations for the Europe, Middle East and Africa (EMEA) Region at QIAGEN. "This agreement expands our assay portfolio, strengthens our position in oncology research, and supports faster, more reproducible results on the QIAcuity platform for our customers."
The partnership aligns with ID Solutions mission to develop its assays for research use only on fully integrated platforms. "Partnering with QIAGEN enables us to extend the reach of our high-quality dPCR assays to more laboratories," said Lise Grewis, CEO, ID Solutions. "Together, we're enabling faster adoption of dPCR in oncology research with robust, reliable results."
For customers, this partnership translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, expanding beyond the current menu, enabling results in less than a day and meeting the growing demand for deeper molecular insights.
To learn more about QIAGEN's dPCR solutions and the new assays available through this partnership, visit https://www.id-solutions.fr/en/idnaptex-range/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
About ID Solutions
ID Solutions is a French company specialized in the development of molecular biology solutions for research and diagnostics in human oncology and infectious diseases. Founded in 2016 and based in Montpellier, ID Solutions has established capabilities for innovation, offering high-performance tools to support oncology departments across France. The company provides comprehensive solutions covering pre-analytical, analytical and interpretation stages, ensuring reliable, rapid and standardized molecular typing results. With a team of specialists in nucleic acid extraction, molecular biology and oncology, ID Solutions is committed to improving patient care through precision medicine and early detection of tumors. For more information, visit www.id-solutions.fr.
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Oncology

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Growth Stocks to Stash and 1 to Question
2 Growth Stocks to Stash and 1 to Question

Yahoo

time12 minutes ago

  • Yahoo

2 Growth Stocks to Stash and 1 to Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.

Tribute Portfolio expands to Buenos Aires, Argentina
Tribute Portfolio expands to Buenos Aires, Argentina

Yahoo

time17 minutes ago

  • Yahoo

Tribute Portfolio expands to Buenos Aires, Argentina

Tribute Portfolio, a collection of independent hotels from Marriott Bonvoy's global portfolio, has opened its first property in Buenos Aires, Argentina. The Recoleta Grand Hotel is situated in the city's Recoleta district. The hotel offers 142 guest rooms, including six suites, all showcasing the porteña culture and French influence through Lucas Gashu's interior designs. Marriott International Caribbean and Latin America president Brian King said: 'The opening of Recoleta Grand marks an exciting chapter for Tribute Portfolio as we continue to expand into Argentina. 'This property captures the essence of what makes the brand so compelling – distinctive design, vibrant spaces, and an authentic connection to place. It's a fitting addition to our growing global collection of independent hotels that celebrate character and creativity at every turn.' The Recoleta Grand offers various dining options while the preserved historical Mansión Mihura hosts spaces such as La Maga, Rayuela, and Serpent Club. In addition to its culinary offerings, the hotel features 3,700ft² of flexible event space, a rooftop terrace, a spa, an executive lounge, and a fitness centre. Recoleta Grand general manager Mauricio Secco said: 'Recoleta Grand is more than a hotel—it's a living narrative of Buenos Aires' rich heritage and vibrant present. 'Every detail, from our literary-inspired spaces to our locally rooted dining experiences, is designed to offer guests a sense of discovery and belonging; in this neighbourhood, the Grand Recoleta Hotel carries forward a legacy of sophistication, offering an atmosphere that feels both timeless and contemporary.' Tribute Portfolio has expanded to more than 155 hotels in over 30 countries and territories. The Buenos Aires launch follows its entrance into the Middle East in May 2024 with The First Collection at Jumeirah Village Circle in Dubai, UAE. "Tribute Portfolio expands to Buenos Aires, Argentina" was originally created and published by Hotel Management Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Enlaps Launches Tikee mini+
Enlaps Launches Tikee mini+

Business Wire

time27 minutes ago

  • Business Wire

Enlaps Launches Tikee mini+

GRENOBLE, France--(BUSINESS WIRE)--Enlaps, the leader in long term project monitoring solutions introduces today Tikee mini+ with brand new features that makes a more powerful timelapse camera with extended capabilities. Following the massive adoption of Tikee mini we have decided to improve drastically the capture experience with Tikee mini+ by offering 6 major new features representing a major breakthrough in project monitoring Share « Following the massive adoption of Tikee mini we have decided to improve drastically the capture experience with Tikee mini+ by offering 6 major new features representing a major breakthrough in project monitoring » said Antoine Auberton-Hervé Co-founder CEO of Enlaps. New Features Include: True View: allow the possibility to choose between the original view 120° super-wide fisheye, 110° view wide angle without distortion, 90° view a higher frame to focus attention on what matters most. Live Preview: Adjust framing directly via the Tikee Remote mobile app to ensure optimal shooting conditions. Low Light Mode: Automatically improves image quality at sunrise or in dim environments, delivering sharp, clean visuals. White Balance Lock: Ensures color consistency across captures, ideal for indoor settings, scientific research, and phenology. Adaptive Interval: Automatically sets the optimal capture frequency to extend battery life and simplify long-term shoots. Rotation Settings: Switch easily between portrait and landscape modes, with no mounting limitations, great for vertical projects and social media formats. Tikee mini+ retains the same ultra-compact design, suitable for both indoor and outdoor use, and supports 4G/LTE and WiFi connectivity. As part of the Enlaps ecosystem, Tikee mini+ is compatible with the myTikee cloud platform, offering immersive content creation and advanced data analysis. Pricing and Availability Tikee mini+ is available today at an unchanged price of 799€/999$ excluding tax. About Enlaps Enlaps designs integrated solutions for small-scale to large-scale site monitoring based on the self-autonomous timelapse camera Tikee (for Timekeeper) connected to a SaaS platform called myTikee in order to provide quality and informative content to companies and professional photographers in the construction, events, smart cities, agriculture, research and tourism sectors.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store